Safinamide

Drugbox
IUPAC_name = (2"S")-2- [4- [(3-Fluorophenyl)methoxy] phenyl] methylamino] propanamide


CAS_number = 133865-89-1
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 131682
DrugBank =
chemical_formula =
C=17 | H=19 | F=1 | N=2 | O=2
molecular_weight = 302.34 g/mol
smiles = C [C@@H] (C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Safinamide is a candidate drug against Alzheimer's disease with multiple methods of action. In 2007, a Phase III clinical trial (Motion: Safinamide add-on to dopamine agonist for early idiopathic Parkinson's disease) was started. It will be marketed by Merck-Serono.

Possible additional uses are restless legs syndrome (RLS) and epilepsy. as of|2008, they are in Phase II.

Methods of action

Parkinson and RLS relevant mechanisms

Safinamide is a monoamine oxidase B inhibitor, reducing degradation of dopamine.

It is a glutamate release inhibitor.

It seems to inhibit dopamine reuptake.

Other mechanisms

Furthermore, safinamide blocks sodium and calcium channels.

References

*cite journal|last=Chazot|first=PL|date=2007|title=Drug evaluation: Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome|journal=Current opinion in investigational drugs|volume=8|pages=570-579
*cite journal|last=Fariello|first=RG|date=2007|title=Safinamide|journal=Neurotherapeutics|volume=4|pages=110-116